Guizhou Sanli Pharmaceutical Co Ltd (603439) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guizhou Sanli Pharmaceutical Co Ltd (603439) has a cash flow conversion efficiency ratio of 0.021x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥33.19 Million ≈ $4.86 Million USD) by net assets (CN¥1.55 Billion ≈ $226.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Guizhou Sanli Pharmaceutical Co Ltd (603439) defensive interval to measure how many days the company can operate on defensive assets alone.
Guizhou Sanli Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Guizhou Sanli Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guizhou Sanli Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guizhou Sanli Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gr. Sarantis S.A.
AT:SAR
|
0.008x |
|
G R Infraprojects Limited
NSE:GRINFRA
|
0.043x |
|
Guangzhou Hongli Opto Electron
SHE:300219
|
0.038x |
|
Corvus Pharmaceuticals Inc
NASDAQ:CRVS
|
-0.043x |
|
PC Jeweller Limited
NSE:PCJEWELLER
|
0.005x |
|
Wuhan LinControl Automotive Electronics Co. Ltd. A
SHG:688667
|
0.053x |
|
Dividend 15 Split Corp
TO:DFN
|
0.030x |
|
Nova Technology
TWO:6613
|
0.056x |
Annual Cash Flow Conversion Efficiency for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Guizhou Sanli Pharmaceutical Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.59 Billion ≈ $233.34 Million |
CN¥107.07 Million ≈ $15.67 Million |
0.067x | -58.52% |
| 2023-12-31 | CN¥1.71 Billion ≈ $250.13 Million |
CN¥276.70 Million ≈ $40.49 Million |
0.162x | -31.66% |
| 2022-12-31 | CN¥1.24 Billion ≈ $181.19 Million |
CN¥293.29 Million ≈ $42.92 Million |
0.237x | +57.68% |
| 2021-12-31 | CN¥1.03 Billion ≈ $151.02 Million |
CN¥155.04 Million ≈ $22.69 Million |
0.150x | +133.21% |
| 2020-12-31 | CN¥981.88 Million ≈ $143.68 Million |
CN¥63.25 Million ≈ $9.26 Million |
0.064x | -63.92% |
| 2019-12-31 | CN¥651.09 Million ≈ $95.27 Million |
CN¥116.24 Million ≈ $17.01 Million |
0.179x | +22.74% |
| 2018-12-31 | CN¥518.02 Million ≈ $75.80 Million |
CN¥75.35 Million ≈ $11.03 Million |
0.145x | +19.81% |
| 2017-12-31 | CN¥473.36 Million ≈ $69.27 Million |
CN¥57.47 Million ≈ $8.41 Million |
0.121x | +48.93% |
| 2016-12-31 | CN¥430.59 Million ≈ $63.01 Million |
CN¥35.10 Million ≈ $5.14 Million |
0.082x | -46.96% |
| 2015-12-31 | CN¥216.53 Million ≈ $31.68 Million |
CN¥33.28 Million ≈ $4.87 Million |
0.154x | +2870.82% |
| 2014-12-31 | CN¥108.92 Million ≈ $15.94 Million |
CN¥563.46K ≈ $82.45K |
0.005x | -98.81% |
| 2013-12-31 | CN¥69.09 Million ≈ $10.11 Million |
CN¥30.09 Million ≈ $4.40 Million |
0.435x | -- |
About Guizhou Sanli Pharmaceutical Co Ltd
Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, includi… Read more